RHHBY - Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? | Benzinga
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers.
In January, Roche terminated the collaboration and licensing agreement for HOOKIPA’s HB-700 program in KRAS mutated cancers.
HOOKIPA’s HB-700 program is designed to treat KRAS-mutated lung, colorectal, pancreatic, and other cancers by targeting the five most prevalent KRAS mutations in these disease indications: G12D, G12V, G12R, G12C, and G13D.
The company says the program ...